文献速递膀胱癌与上尿路尿路上皮癌

个体化肿瘤知情循环肿瘤DNA检测在EV±P治疗晚期尿路上皮癌中的预后价值

Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.
PubMed 文献 · Eur Urol Oncol · 2026-06-30

这项多中心真实世界回顾性探索性分析纳入110例接受EV±P治疗的局部晚期或转移性尿路上皮癌患者,共545份血浆样本。基线ctDNA检出率93.6%,治疗中ctDNA阳性在各时间区间均与更差的无进展生存和总生存独立相关,12周内持续阳性预后更差,早期清除多见于影像学缓解者。

要点

  • 治疗中ctDNA阳性与EV±P治疗患者更差的PFS和OS独立相关。
  • 12周内ctDNA持续阳性者PFS和OS显著缩短。
  • 早期ctDNA清除在影像学缓解者中更常见。

核心结论

  • 个体化肿瘤知情ctDNA检测可提示EV±P治疗反应并预后生存获益。

研究设计与样本

  • 探索性、真实世界、回顾性、多中心分析,纳入110例接受EV±P治疗的la/mUC患者,共545份血浆样本,中位随访60.6周。

主要发现

  • 基线ctDNA检出率93.6%,12周内75.8%下降、33.9%清除。
  • 治疗中ctDNA阳性与更差PFS相关:4-12周HR=10.08(p<0.001),12-24周HR=11.84(p<0.001),>24周HR=6.77(p<0.001)。
  • 治疗中ctDNA阳性与更差OS相关:4-12周HR=6.53(p=0.013),12-24周HR=7.22(p=0.0083),>24周HR=3.81(p=0.025)。
  • 12周内持续阳性与更短PFS(HR=8.96,p=0.0004)和OS(HR=4.58,p=0.016)相关。
  • 早期ctDNA清除在影像学缓解者中更常见(p<0.001)。

临床怎么用

  • 可考虑用连续ctDNA监测辅助判断EV±P治疗反应与预后风险。

局限性

  • 回顾性设计。
  • ctDNA采样未标准化。
  • 评估和治疗方式存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Enfortumab vedotin (EV) plus pembrolizumab (P) is the preferred first-line therapy for locally advanced or metastatic urothelial carcinoma (la/mUC); however, responses remain heterogeneous, and biomarkers are limited. We evaluated longitudinal tumor-informed circulating tumor DNA (ctDNA) as a potential real-time prognostic biomarker in patients with la/mUC initiating EV with or without P (EV±P). DESIGN, SETTING AND PARTICIPANTS: This is an exploratory, real-world retrospective, multicenter analysis of patients with la/mUC who received personalized, tumor-informed ctDNA testing (Signatera, Natera, Inc.) coinciding with their EV±P treatment. RESULTS AND LIMITATIONS: Across 545 plasma samples from 110 patients (median follow-up 60.6 weeks (wk)), baseline ctDNA was detected in 93.6% and declined or cleared within 12 wk in 75.8% and 33.9%, respectively. In all evaluated time intervals, ctDNA positivity on-treatment was consistently associated with inferior progression-free survival (PFS) and overall survival (OS) compared to ctDNA negativity (PFS 4-12 wk: hazard ratio [HR] = 10.08; p < 0.001; 12-24 wk: HR = 11.84; p < 0.001; >24 wk: HR = 6.77; p < 0.001; OS 4-12 wk: HR = 6.53; p = 0.013; 12-24 wk: HR = 7.22; p = 0.0083; >24 wk: HR = 3.81; p = 0.025) and remained independently prognostic on multivariable analyses. ctDNA dynamics relative to baseline were similarly prognostic: persistent positivity within 12 wk was associated with shorter PFS (HR = 8.96; p = 0.0004) and OS (HR = 4.58; p = 0.016), whereas early ctDNA clearance was enriched among radiographic responders (p < 0.001). Limitations include the retrospective design, non-standardized ctDNA sample collection, and heterogeneity in evaluation and treatment approaches. CONCLUSIONS: Personalized, tumor-informed ctDNA testing can indicate response to EV±P and is prognostic of survival benefit in patients with la/mUC receiving EV±P.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Reyes KR, Zhu R, Herberts C, et al. Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab. Eur Urol Oncol. 2026. PMID: 42379901. doi:10.1016/j.euo.2026.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。